Investment Rating - The report assigns an "Outperform" rating to multiple companies including Nike, Midea Group, JD Group, and Anta Sports, among others [1]. Core Insights - Concerns regarding the independence of the Federal Reserve and future monetary policy stability have led to a collective decline in overseas consumer sectors [4][11]. - The snack sector has shown resilience, outperforming the MSCI China index, while other sectors such as luxury goods and overseas sportswear have faced significant declines [4][11]. - The report highlights that most sectors are currently undervalued compared to their historical averages, indicating potential investment opportunities [9][15]. Sector Performance Summary - **Snack Sector**: Increased by 1.7%, with Wei Long's revenue guidance for 2026 projected to grow over 15% due to innovative products and channel expansion [6][14]. - **Jewelry Sector**: Rose by 1.6%, driven by Chow Tai Fook's strong operational performance expectations for FY26Q3 [6][14]. - **Overseas Cosmetics**: Gained 1.1%, with E.L.F Beauty's sales growth exceeding previous guidance [6][14]. - **Domestic Sportswear**: Increased by 1.5%, with Li Ning's revenue meeting expectations and a positive outlook for net profit margins [8][14]. - **Pet Sector**: Grew by 0.3%, with strong annual growth despite a slight decline in December [8][14]. - **Gambling Sector**: Slight decline of 0.1%, with Galaxy Entertainment showing resilience as a preferred investment choice [8][14]. - **Domestic Cosmetics**: Decreased by 0.3%, with expectations for recovery in 2026 [8][14]. - **Retail Sector**: Fell by 1.5%, with Target's positive leadership changes noted [8][14]. - **Luxury Goods**: Declined by 2.9%, impacted by market concerns over credit risks following Saks Global's bankruptcy [8][14]. - **Overseas Sportswear**: Experienced a significant drop of 4.0%, with major brands like Nike and Adidas facing declines [8][14]. - **Credit Card Sector**: Decreased by 5.1%, influenced by proposed caps on credit card interest rates [8][14]. Valuation Analysis - The report indicates that the expected PE ratios for various sectors in 2025 are below their historical averages, suggesting potential undervaluation: - Overseas Sportswear: 30.4x (57% of historical average) - Domestic Sportswear: 13.5x (71% of historical average) - Jewelry: 22.8x (43% of historical average) - Luxury Goods: 27.4x (49% of historical average) - Gambling: 16.2x (26% of historical average) - Overseas Cosmetics: 41.0x (61% of historical average) - Domestic Cosmetics: 27.3x (51% of historical average) - Pet Sector: 36.9x (50% of historical average) - Snack Sector: 29.8x (72% of historical average) - Retail: 29.9x (54% of historical average) - US Hotels: 34.8x (21% of historical average) - Credit Cards: 28.3x (54% of historical average) [9][15].

Investment Rating - The report assigns an "Outperform" rating to several companies including Pop Mart, Anta Sports, Huazhu Group, Li Ning, Miniso, Atour Group, and Xtep International, with target prices ranging from 6.99 to 354.00 [1]. Core Insights - The integration of AI and advertising models is gradually taking effect, with Generative Engine Optimization (GEO) expected to dominate the traffic competition in the AI-driven search era. The GEO market is projected to grow significantly, with a forecasted global market size of USD 11.2 billion in 2025, reaching USD 100.7 billion by 2030 [3][13]. - Key companies in the sector, such as Qingmu Technology, are actively developing their e-commerce ecosystems and leveraging proprietary systems to enhance their market position [4]. Company Performance - Top performers this week include Guoquan (+11.9%), Haidilao (+10.7%), Nayuki (+6.5%), SuperHi (+5.4%), and Hisense (+3.8%). Conversely, underperformers include JS Global Life (-4.6%), Roborock (-5.2%), TCL Electronics (-6.3%), Chagee (-8.2%), and Pop Mart (-9.3%) [6][14]. - Haidilao has appointed Zhang Yong as CEO, aiming to bring new perspectives and enhance board efficiency [8][15]. Industry Dynamics - Qdama and YUEN KEE FOOD have submitted listing applications to the Hong Kong Stock Exchange, with projected revenues showing growth [11][12]. - Big Catering has also submitted a listing application, with significant revenue growth reported for 2024 and Q3 2025 [12].

Investment Rating - The report maintains a "Neutral" rating for Coca-Cola Co (KO US) with a current price of US$70.48 and a target price of US$71.38 [2]. Core Insights - The franchise restructuring is expected to be completed by 2026, aiming for an operating profit margin of 30-35%. Key steps include the sale of a 40% stake in Indian bottling operations and partial interests in African bottling businesses [3][12]. - Coca-Cola China's bottling partners are projected to achieve mid-single-digit revenue growth, supported by significant upgrades to production facilities, including a smart green production base in Guangdong [4][13]. - A smooth CEO transition is anticipated as COO Henrique Braun is set to succeed James Quincey on March 31, 2026, with expectations for continued strategic execution [5][14]. - The company is expected to unlock new growth opportunities in India and enhance its total beverage portfolio through the performance of its protein drink brand, Fairlife [6][15]. Financial Summary - Revenue projections for Coca-Cola are as follows: - 2025: US$48.046 billion - 2026: US$51.221 billion - 2027: US$53.836 billion - Corresponding net profits are projected at US$12.874 billion, US$13.951 billion, and US$14.775 billion for the same years [2][10]. - The diluted EPS is forecasted to be US$2.98 in 2025, US$3.24 in 2026, and US$3.45 in 2027, with a P/E ratio of 24 for 2025 and decreasing to 20 by 2027 [2][10].

Investment Focus - Since the beginning of 2026, the Shanghai Composite Index has broken above the 4,000 and 4,100 thresholds and is approaching 4,200, indicating signs of market overheating with significant inflows into commercial aerospace and AI application sectors, leading to a record turnover of RMB 3.6 trillion [1][26] - Margin financing inflows reached RMB 91.2 billion over the first four trading days of the week, with outstanding margin balances exceeding RMB 2.7 trillion, reflecting a strong inflow intensity comparable to the cyclical highs of August-September 2025 [1][26] - Retail investor inflows have been consistently rising, indicating increased participation from individual investors [1][26] Regulatory Environment - On January 15, 2026, the China Securities Regulatory Commission emphasized a "stability-first" approach to consolidate market momentum and prevent extreme fluctuations, including raising the minimum margin financing collateral ratio from 80% to 100% [2][27] - A significant net outflow of RMB 66.809 billion was recorded in broad-based A-share ETFs on January 15, marking the highest outflow on record, with the Huatai-PineBridge CSI300 ETF experiencing a net outflow of RMB 20.157 billion [2][27] - The relocation of high-frequency traders' servers is expected to enhance trading fairness and curb excessive speculation, which may dampen short-term speculative sentiment but not alter the medium-term market trend [2][27] Market Outlook - The market may enter a phase of consolidation as regulatory cooling measures take effect, particularly affecting previously leading sectors like commercial aerospace, which saw significant declines [3][28] - Despite short-term fluctuations, a slow-bull trend remains a common goal for both regulators and long-term capital, suggesting that the spring rally is not over but may require a "washout" for a healthier uptrend [3][28] Investment Strategy - During the consolidation phase, it is recommended to remain patient while maintaining a medium-term bullish outlook, focusing on identifying Chinese assets with strong medium-to-long-term value [3][29] - A-shares and Hong Kong equities are expected to complement each other, with Hong Kong tech stocks likely to outperform A-shares in the near term due to upcoming AI product launches [3][29] - Investors are advised to align with regulatory intentions to curb speculative trading and focus on structural opportunities in sectors such as semiconductors, innovative drugs, and Hong Kong tech leaders [3][30] Sector Highlights - **Semiconductors**: TSMC's 2026 capex guidance is set at USD 52-56 billion, exceeding 100% of its previous year's operating cash flow, indicating strong demand driven by AI [3][30] - **Innovative Drugs**: The healthcare sector has seen a net outflow of RMB 4.3 billion over the past four months, contrasting sharply with previous inflows, while remaining in a favorable policy environment with new drug listings [3][32] - **Hong Kong Tech Leaders**: Companies like Alibaba and Tencent are integrating AI into their ecosystems, with strong growth in overseas business for Alibaba Cloud and potential upgrades for Baidu's listing status [3][33] - **Optical Modules**: Following significant gains, the sector is now in a consolidation phase, with a shift towards earnings certainty as A-shares enter the annual results pre-announcement window [3][34]

Group 1 - Investment Rating: Rated 'Outperform' with a target price of RMB 31.68 based on a 22x PE for 2026 [4][10] - Core View: The company is expected to have strong performance in 2025 with total revenue of RMB 85.90 billion, up 1.65% YoY, and net profit of RMB 34.20 billion, up 5.14% YoY, driven by increased electricity sales and reduced finance expenses [12][11] - High water inflow and storage in Q4 2025 ensure power generation in H1 2026, with total power generation of six domestic stations reaching approximately 307.20 billion kWh, a 3.82% YoY increase [11][10] Group 2 - Financial Highlights: The company projects EPS for 2025-27 at RMB 1.40/1.44/1.53, with a net profit margin expected to remain strong [4][10] - Cash Dividend Policy: The company plans to distribute at least 70% of net profit as cash dividends from 2026 to 2030, with a projected dividend per share of RMB 0.9775 for 2025, yielding 3.6% based on the closing price [13][12] - Financial Metrics: The company’s net profit attributable to shareholders is projected to grow steadily, with a net profit margin of 40.3% expected by 2025 [3][12]

Financial Impact - Ctrip (TCOM) is under investigation for alleged monopolistic practices, with a potential fine estimated at RMB 1.5 billion, representing 4% of its 2024 domestic revenue[2][5] - The financial impact of the fine is considered limited, with a projected net profit margin decrease of 2 percentage points for the 2026 fiscal year[5][10] Revenue Projections - Ctrip's total revenue for the 2026 fiscal year is expected to reach RMB 70.1 billion, reflecting a 13% year-on-year growth[10][11] - Domestic accommodation revenue is projected to grow by 3% year-on-year, while overall accommodation revenue is expected to increase by 13%[10][11] Profitability Metrics - Non-GAAP operating profit for 2026 is estimated at RMB 19.1 billion, a 5% increase from the previous year, with a profit margin of 27%, down 2 percentage points[10][11] - The net commission rate is expected to stabilize at 8.8%, which is within the historical range of 8%-10%[10][11] Market Position and Risks - Ctrip is expected to maintain its leading position in the online travel market, but faces risks of market share loss due to regulatory pressures and competition[8][9] - Potential loss of price-sensitive customers and hotel inventory could occur if Ctrip allows merchants to set their own prices without inventory lock-in[9] Valuation Outlook - Ctrip's valuation may revert to historical levels of 12-15 times earnings, with the stock price potentially dropping to a range of USD 44-55 per ADR[15] - The company’s valuation has been driven by strong revenue growth and profit margin expansion, but regulatory scrutiny may hinder future profitability[15]

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 6.83 HKD, reflecting a 9% downside based on a 2025 PE of 10X [8][11]. Core Insights - The company focuses on mass professional sports, leading industry turnover growth, and is committed to technological innovation and product upgrades, with rapid expansion of super stores [8][10]. - The company achieved steady turnover growth in Q4 2025, with main brand offline, online, and children's turnover growing by 10%, high double digits, and 10% year-on-year respectively [9][10]. - The company exceeded its annual opening target for super stores, with 126 stores opened by the end of 2025, surpassing the initial target of 100 stores [10][11]. - The company is increasing its focus on mental products and professional events, with successful product launches and event sponsorships planned for 2026 [11]. Financial Summary - Projected total revenue for 2024A, 2025E, 2026E, and 2027E is 10,074 million, 11,147 million, 12,355 million, and 13,732 million RMB respectively, reflecting growth rates of 19.6%, 10.7%, 10.8%, and 11.1% [3]. - Projected net profit attributable to shareholders for 2025-2027 is 1,271 million, 1,403 million, and 1,560 million RMB, with corresponding PE ratios of 8.5X, 7.7X, and 6.9X [3][8]. - The company’s gross profit is expected to increase from 4,183 million RMB in 2024A to 5,633 million RMB in 2027E, maintaining a gross margin around 40% [3].

Acquisitions - Charles River announced the strategic acquisition of K.F. (Cambodia) Ltd. for approximately $510 million, expected to complete in Q1 2026, to self-supply most annual NHP needs[4] - The company will also acquire the remaining 79% of PathoQuest for about €51.60 million (approximately $60 million), expected to contribute $15-20 million in revenue in 2026[4] Supply Chain and Technology Enhancement - The acquisition of K.F. will aid in vertical integration amid global NHP resource constraints, enhancing DSA business stability and cost control[5] - PathoQuest's NGS quality control technology will improve NAMs and bioproduct quality control, increasing the proportion of high-value services[5] DSA Demand Recovery - DSA net book-to-bill ratio reached 1.1x in Q4 2025, up from 0.8x in Q2-Q3 2025, indicating a recovery driven by small and medium biotech demand and growth in large pharma orders[6] - This recovery signals a gradual bottoming out of preclinical demand[6] 2026 Performance Outlook - The company is cautiously optimistic for 2026, expecting organic revenue growth to be at least flat, with DSA business resuming organic growth in H2 2026[6] - Forex is expected to contribute 100-150 basis points to revenue growth[6] Investment Recommendations - Long-term positive outlook on pharmaceutical growth, with a focus on domestic companies such as WuXi AppTec and Pharmaron[7] - Suggested companies to watch include WuXi AppTec, Pharmaron, JOINN Laboratories, and others[7] Risk Factors - Risks include a weaker-than-expected global biotech financing environment and challenges in NHP supply chain recovery[7] - Potential risks related to acquisition integration and project execution[7]

Investment Rating - The report initiates coverage with an OUTPERFORM rating, setting a target price of RMB 206.00 based on a current price of RMB 165.46 [2]. Core Insights - The company, Sungrow Power Supply, is positioned as a leader in the global photovoltaic inverter market and is experiencing significant growth in its energy storage business, which is expected to become the primary growth engine [3][5]. - The global photovoltaic installation demand is projected to continue its long-term growth trend, with new installations expected to reach approximately 610GW in 2025 and 642GW in 2026 [4][33]. - The energy storage market is anticipated to see a compound annual growth rate (CAGR) exceeding 50% from 2021 to 2027, with large-scale storage installations expected to rise from 28.4GWh to 605GWh [5][42]. Company Overview - Sungrow Power Supply was established in 1997 and went public in 2011, focusing on the research, production, and sales of renewable energy equipment, including photovoltaic, wind, storage, and hydrogen energy technologies [9][11]. - The company has built a comprehensive industrial chain covering core equipment manufacturing, system integration, and energy services, forming a synergistic ecosystem [9][10]. Photovoltaic Inverters - The company maintains a leading market share in photovoltaic inverters, with a global shipment volume of 147GW in 2024, representing a year-on-year growth of 13.08% and a market share of approximately 23%-25% [4][41]. - The product matrix includes a range of inverters suitable for various applications, from residential to large-scale ground-mounted power plants, ensuring a robust global presence [3][10]. Energy Storage - The energy storage business is expected to surpass the photovoltaic inverter segment as the primary growth driver by 2025, with significant orders and a high proportion of overseas orders [5][42]. - The company has developed advanced energy storage solutions, including the PowerTitan liquid-cooled storage system, which has been successfully implemented in major projects [10][42]. Financial Performance - For the first three quarters of 2025, the company reported revenues of RMB 664.02 billion, a year-on-year increase of 32.95%, and a net profit of RMB 118.81 billion, reflecting a substantial growth of 56.34% [22][23]. - The gross profit margin improved to 34.88%, indicating enhanced profitability and cash flow management [22][23]. Global Expansion - Sungrow Power Supply has expanded its operations to over 180 countries, with a strong presence in Europe, North America, the Middle East, and emerging markets [30][42]. - The company is well-positioned to benefit from the increasing demand for renewable energy solutions globally, particularly in large-scale storage projects [42][46].

Investment Rating - The report indicates a positive outlook for the AI+Pharma and AI+Healthcare sectors, suggesting a shift towards data and algorithm-driven drug development and clinical applications [3][6]. Core Insights - The collaboration between NVIDIA and Eli Lilly to establish the first AI+Pharma joint innovation lab signifies a major step in integrating AI into drug R&D, with a planned investment of up to 1 billion USD over five years [3][6]. - Tempus AI's preliminary revenue for 2025 reached approximately 1.27 billion USD, reflecting an 83% year-over-year growth, validating the commercial viability of AI in clinical testing and medical data [3][6]. - The industry is currently experiencing a phase characterized by technological breakthroughs, active funding, and accelerated application of AI in pharmaceuticals and healthcare [3][6]. Summary by Sections AI+Pharma - The establishment of the AI+Pharma lab aims to address key challenges in drug development, combining expertise from both NVIDIA and Eli Lilly [3][6]. - The partnership is expected to elevate AI's role from a mere tool to a core productivity driver in drug R&D, transitioning the industry from experience-driven to data-driven methodologies [3][6]. AI+Healthcare - Tempus AI reported a diagnostic revenue of approximately 955 million USD, up 111% year-over-year, driven by significant growth in oncology and genetic testing [3][6]. - The data and application segment generated about 316 million USD, marking a 31% increase, with data licensing (Insights) growing by 38% [3][6]. Industry Trends - The report highlights a favorable environment for AI in pharmaceuticals, supported by technological advancements, policy backing, and a vibrant investment landscape [3][6]. - The launch of OpenAI's ChatGPT Health and the significant user engagement indicate a growing interest and application of AI technologies in healthcare [3][6]. - Relevant investment targets in AI drug discovery and healthcare applications include companies like XtalPi, Insilico Medicine, and Meinian Onehealth [3][6].